Investigators sought to determine the prevalence of small intestinal bacterial overgrowth and establish its prognostic value in patients with heart failure.
Primary effectiveness of no additional surgical or interventional procedures related to the device and acceptable heart blood flow function at 6 months, was achieved by 89.2%.
February is American Heart Month, and patients who have been diagnosed with cancer are part of a group that is uniquely vulnerable to cardiovascular disease. What risk factors should these patients know about for fatal heart disease?
January 2021 FDA approvals of import to physician assistants and nurse practitioners include treatments for HIV, heart failure, dry eye disease, and light chain amyloidosis.
The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.
